Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

The Effects after Implementing a Drug Utilization Review System on Contraindicated Drug use: A Systematic Review

사용금기 약물에 대한 의약품안전사용서비스의 효과에 대한 체계적 문헌고찰

  • Lee, Heeyoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gachon University) ;
  • Choi, Hyea Suk (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gachon University) ;
  • Ji, Eunhee (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gachon University)
  • Received : 2018.11.22
  • Accepted : 2019.03.08
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The objective of the present study was to evaluate the effects of implementing a systematic Drug Utilization Review (DUR) system on contraindicated drug use and pharmaceutical expenditures in Korea. Methods: A literature search was conducted using search engines such as PubMed, EMBASE, NDSL, and RISS for relevant systematic studies. The database search was performed and updated in April 2018. Two independent reviewers evaluated the abstracts to find potentially eligible articles. Results: In total, 1433 potentially eligible studies were selected, and 11 articles were eventually shortlisted for inclusion in the present review system. The outcome showed that contraindicated drug use decreased after implementation of the DUR system in Korea. The analysis also showed that the DUR system contributed to a reduction in pharmaceutical expenditures. Conclusions: Our study showed that implementing the DUR system reduced both contraindicated drug use and pharmaceutical expenditures in Korea.

Keywords

References

  1. Hennessy S, Soumerai SB, Lipton HL, Strom BL. Drug utilization review. Pharmacoepidemiology 2006;439-53.
  2. Fulda TR, Lyles A, Pugh MC, Christensen DB. Current status of prospective drug utilization review. J Manag Care Pharm 2004;10:433-41.
  3. Youn SH, Lee SS, Kim S, et al. Drug utilization review of mupirocin ointment in a Korean university-affiliated hospital. Korean J Intern Med 2015;30:515-20. https://doi.org/10.3904/kjim.2015.30.4.515
  4. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005;28:67-80. https://doi.org/10.2165/00002018-200528010-00005
  5. Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med 2011;125:803-15. https://doi.org/10.1007/s00414-010-0536-3
  6. Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. Nephrol Dial Transplant 2011;26:2852-9. https://doi.org/10.1093/ndt/gfq827
  7. Heaton A. High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan. J Manag Care Pharm 2002;8:199-203. https://doi.org/10.18553/jmcp.2002.8.3.199
  8. Jones JK, Fife D, Curkendall S, Goehring E, Jr., Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001;286:1607-9. https://doi.org/10.1001/jama.286.13.1607
  9. Lyles A, Zuckerman IH, DeSipio SM, Fulda T. When Warnings Are Not Enough: Primary Prevention Through Drug Use Review: To avoid adverse drug interactions, clinical data should follow the patient in the same way that financial data do. Health Aff (Millwood) 1998;17:175-83. https://doi.org/10.1377/hlthaff.17.5.175
  10. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284:3036-9. https://doi.org/10.1001/jama.284.23.3036
  11. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86. https://doi.org/10.1002/pds.1193
  12. Moja L, Kwag KH, Lytras T, et al. Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. Am J Public Health 2014;104:e12-e22.
  13. Song SO, Jung CH, Song YD, et al. Background and data configuration process of a nationwide population-based study using the korean national health insurance system. Diabetes Metab J 2014;38:395-403. https://doi.org/10.4093/dmj.2014.38.5.395
  14. Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions-Systematic review and methodological considerations. Br J Clin Pharmacol 2018;84:419-33. https://doi.org/10.1111/bcp.13469
  15. Vander Stichele R, Elseviers M, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004;58:419-28. https://doi.org/10.1111/j.1365-2125.2004.02164.x
  16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87. https://doi.org/10.1016/S0140-6736(05)70799-6
  17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. https://doi.org/10.1186/2046-4053-4-1
  18. Heo JH, Suh DC, Kim S, Lee EK. Evaluation of the pilot program on the real-time drug utilization review system in South Korea. Int J Med Inform 2013;82:987-95. https://doi.org/10.1016/j.ijmedinf.2013.07.001
  19. Lee SO, Je NK, Kim D-S, Hwang IO, Cheun BO. Tiering 'Drug Combinations to Avoid' and 'Drug-age Precaution' DUR Alerts by Severity Level and its Application. Yakhak Hoeji 2015;59:278-83. https://doi.org/10.17480/psk.2015.59.6.278
  20. Yi M-H, Chung W, Cho E, Kim R, Lee S. Factors associated with changes in pharmaceutical expenditures of outpatient care in clinic setting: Focusing on the incentive scheme to reduce total prescribed drug expenditure and the drug utilization review system. Health Policy and Management 2012;22:561-78. https://doi.org/10.4332/KJHPA.2012.22.4.561
  21. Kim SO and Park S. Evaluation of Medication Duplication Management Program for Medicaid patients in South Korea. The Korean Journal of Health Economics and Policy 2014;20:01-19.
  22. Kim D-S, Park J, Jeon H-R, Park C, Kang HA. The Effect of Korean Prospective Drug Utilization Review Program on the Prescription Rate of Drug-Drug Interactions. Health Policy and Management 2014;24:120-7. https://doi.org/10.4332/KJHPA.2014.24.2.120
  23. Shin JY, Kim MH, Shin SM, Lee SH, Park BJ. Dramatic decrease in fluoroquinolones in the pediatric population in Korea. Pharmacoepidemiol Drug Saf 2014;23:1320-4. https://doi.org/10.1002/pds.3696
  24. Shin JY, Lee SH, Shin SM, Shin HN, Park BJ. Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea. Regul Toxicol Pharmacol 2015;72:244-8. https://doi.org/10.1016/j.yrtph.2015.04.022
  25. Yang JH, Kim M, Park YT, Lee EK, Jung CY, Kim S. The effect of the introduction of a nationwide DUR system where local DUR systems are operating--The Korean experience. Int J Med Inform 2015;84:912-9. https://doi.org/10.1016/j.ijmedinf.2015.08.007
  26. Song I, Choi SH, Shin JY. Trends in prescription of pregnancy-contraindicated drugs in Korea, 2007-2011. Regul Toxicol Pharmacol 2016;75:35-45. https://doi.org/10.1016/j.yrtph.2015.12.011
  27. Song I, Shin HN, Shin JY. Decrease in use of contraindicated drugs with automated alerts in children. Pediatr Int 2017;59:720-6. https://doi.org/10.1111/ped.13258
  28. Song SY, Shin JH, Hyeon SY, et al. Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. PLoS ONE 2017; 12 DOI 10.1371/journal.pone.0176420.
  29. Armstrong PW and Mant MJ. Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. Eur Heart J 1995;16:75-80. https://doi.org/10.1093/eurheartj/16.suppl_L.75
  30. Bryant AD, Fletcher GS, Payne TH. Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 2014;5:802-13. https://doi.org/10.4338/ACI-2013-12-RA-0103
  31. Allen LaPointe NM, Chen AY, Roe MT, et al. Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. Am J Cardiol 2009;104:1324-1329 DOI 10.1016/j.amjcard.2009.06.054.
  32. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63. https://doi.org/10.1016/j.amjmed.2010.09.012
  33. Soumerai SB and Lipton HL. Computer-based drug-utilization review--risk, benefit, or boondoggle? NEJM 1995;332:1641-5 DOI 10.1056/nejm199506153322411.
  34. Kim JY, Kim SJ, Nam CM, Moon KT, Park EC. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea. Eur J Public Health 2018;28:209-14 DOI 10.1093/eurpub/ckx168.
  35. Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuticals In Europe: Striving for Efficiency, Equity and Quality. Berkshire: McGraw-Hill Education (UK), 2004;1-2.
  36. Maynard A and Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood) 2003;22:31. https://doi.org/10.1377/hlthaff.22.3.31

Cited by

  1. 의약 정보검색을 위한 ATC코드기반 매핑 스키마 설계 vol.12, pp.3, 2019, https://doi.org/10.15207/jkcs.2021.12.3.053